Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Yu‐Shui Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5728-7458; OpenAlex author ID A5014828679. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. Artificial intelligence-driven early screening and diagnosis of pancreatic cancer: technical innovations, clinical applications, and precision medicine strateg… Co-author DOI 10.1016/j.jare.2026.04.060↗
  2. The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer. Co-author DOI 10.1016/j.jare.2024.01.014↗
  3. KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA network. Co-author DOI 10.1016/j.heliyon.2024.e24287↗
  4. microRNA-873 inhibits self-renewal and proliferation of pancreatic cancer stem cells through pleckstrin-2-dependent PI3K/AKT pathway. First author DOI 10.1016/j.cellsig.2021.110025↗
  5. Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition. Co-author DOI 10.1186/s12967-021-03052-5↗
  6. Differential expression profiling of microRNAs in para-carcinoma, carcinoma and relapse human pancreatic cancer. Co-author DOI 10.1007/s12094-014-1249-8↗
  7. Differential gene expression of the key signalling pathway in para-carcinoma, carcinoma and relapse human pancreatic cancer. Co-author DOI 10.1002/cbf.3009↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Da Fu · 6 shared papers, 2014–2025 · strength 0.69
  2. Xiaomei Tang · 2 shared papers, 2024–2025 · strength 0.39
  3. Yang Li · 1 shared paper, 2026 · strength 0.24
  4. Pei Xue · 1 shared paper, 2026 · strength 0.24
  5. Xiao‐Li Yang · 2 shared papers, 2021 · strength 0.22
  6. Hong Yu · 1 shared paper, 2025 · strength 0.21
  7. Yizhi Cao · 1 shared paper, 2025 · strength 0.21
  8. Yunfeng Wang · 1 shared paper, 2025 · strength 0.21
  9. Hong Jiang · 1 shared paper, 2025 · strength 0.21
  10. Haoyu Tang · 1 shared paper, 2025 · strength 0.21
  11. Hong Yu · 1 shared paper, 2024 · strength 0.18
  12. Meng Zhang · 1 shared paper, 2024 · strength 0.18
  13. Zhengyan Chang · 2 shared papers, 2014–2015 · strength 0.08
  14. W.-P. Li · 1 shared paper, 2015 · strength 0.04
  15. Yunlong Li · 1 shared paper, 2015 · strength 0.04
  16. Xuntao Lai · 1 shared paper, 2015 · strength 0.04
  17. Xiaoping Zhang · 1 shared paper, 2014 · strength 0.04
  18. Wenping Li · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.